147 related articles for article (PubMed ID: 9438871)
1. Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors.
Toledo LM; Lydon NB
Structure; 1997 Dec; 5(12):1551-6. PubMed ID: 9438871
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2.
Lawrie AM; Noble ME; Tunnah P; Brown NR; Johnson LN; Endicott JA
Nat Struct Biol; 1997 Oct; 4(10):796-801. PubMed ID: 9334743
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.
Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP
Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460
[TBL] [Abstract][Full Text] [Related]
4. X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research.
Furet P
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):15-23. PubMed ID: 12678911
[TBL] [Abstract][Full Text] [Related]
5. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
[TBL] [Abstract][Full Text] [Related]
6. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.
Johnson LN; De Moliner E; Brown NR; Song H; Barford D; Endicott JA; Noble ME
Pharmacol Ther; 2002; 93(2-3):113-24. PubMed ID: 12191604
[TBL] [Abstract][Full Text] [Related]
7. Complex regulation of CDK2 and G1 arrest during neuronal differentiation of human prostatic cancer TSU-Prl cells by staurosporine.
Shimizu T; Takahashi N; Tachibana K; Takeda K
Anticancer Res; 2001; 21(2A):893-8. PubMed ID: 11396181
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
9. Under arrest at atomic resolution.
Morgan DO
Nature; 1996 Jul; 382(6589):295-6. PubMed ID: 8684452
[No Abstract] [Full Text] [Related]
10. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
11. Stoichiometry of cyclin A-cyclin-dependent kinase 2 inhibition by p21Cip1/Waf1.
Adkins JN; Lumb KJ
Biochemistry; 2000 Nov; 39(45):13925-30. PubMed ID: 11076534
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.
Davies TG; Tunnah P; Meijer L; Marko D; Eisenbrand G; Endicott JA; Noble ME
Structure; 2001 May; 9(5):389-97. PubMed ID: 11377199
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.
Legraverend M; Tunnah P; Noble M; Ducrot P; Ludwig O; Grierson DS; Leost M; Meijer L; Endicott J
J Med Chem; 2000 Apr; 43(7):1282-92. PubMed ID: 10753466
[TBL] [Abstract][Full Text] [Related]
14. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
Sims PA; Wong CF; McCammon JA
J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.
Jeffrey PD; Russo AA; Polyak K; Gibbs E; Hurwitz J; Massagué J; Pavletich NP
Nature; 1995 Jul; 376(6538):313-20. PubMed ID: 7630397
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.
De Azevedo WF; Mueller-Dieckmann HJ; Schulze-Gahmen U; Worland PJ; Sausville E; Kim SH
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2735-40. PubMed ID: 8610110
[TBL] [Abstract][Full Text] [Related]
17. Alternative binding modes of an inhibitor to two different kinases.
De Moliner E; Brown NR; Johnson LN
Eur J Biochem; 2003 Aug; 270(15):3174-81. PubMed ID: 12869192
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for chemical inhibition of CDK2.
Kim SH; Schulze-Gahmen U; Brandsen J; de Azevedo Júnior WF
Prog Cell Cycle Res; 1996; 2():137-45. PubMed ID: 9552391
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.
Schoepfer J; Fretz H; Chaudhuri B; Muller L; Seeber E; Meijer L; Lozach O; Vangrevelinghe E; Furet P
J Med Chem; 2002 Apr; 45(9):1741-7. PubMed ID: 11960485
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
Ducrot P; Legraverend M; Grierson DS
J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
